Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
I read the editorial by Canfell and agree that although there is no
present evidence that the new HPV vaccine can increase the risk for
pregnancy the post marketting surveillane of the vaccine for this specific
possible adverse effect and others, similar to any new drugs, is required.
Indeed, since the HPV vaccine is not a pandemic vaccine, the long term pre
-registration assessment should already confirmed for the safety of
vaccine.
Indeed, the efficacy of HPV vaccination during pregnancy is
interesting. The topic concerns not only safety but also effectiveness. A
new report from a study group in USA also found that "vaccination prior to
pregnancy is unlikely to be efficacious in preventing vertical
transmission [2]."
There are some cencerns for the future using of HPV vaccine after the
post implementation assessment data is derived. The reanalysis of cost-
benefit of this new vaccination should be done. Risk and benefit have to
be weighted for making decision.
2. Smith EM, Parker MA, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP.
Evidence for vertical transmission of HPV from mothers to infants. Infect
Dis Obstet Gynecol. 2010;2010:326369.
I gratefully acknowledge Dr. Julia Brotherton's contribution, and
also that of the following individuals in relation to confirmation of
specific points or review of a draft: Ms. Megan Smith, Prof. Ian Frazer
and Prof. Bruce Armstrong. I also wish to acknowledge personal
communication from Dr. Aleksandra Caric, consultant to the Department of
Immunization, Vaccines & Biologicals, World Health Organization, in
relation to the information considered by the WHO’s Global Advisory
Committee on Vaccine Safety (GACVS) in mid-2009.
Competing interests:
As described in the Editorial
HPV vaccination program: post marketting surveillane and next step
Editor,
I read the editorial by Canfell and agree that although there is no
present evidence that the new HPV vaccine can increase the risk for
pregnancy the post marketting surveillane of the vaccine for this specific
possible adverse effect and others, similar to any new drugs, is required.
Indeed, since the HPV vaccine is not a pandemic vaccine, the long term pre
-registration assessment should already confirmed for the safety of
vaccine.
Indeed, the efficacy of HPV vaccination during pregnancy is
interesting. The topic concerns not only safety but also effectiveness. A
new report from a study group in USA also found that "vaccination prior to
pregnancy is unlikely to be efficacious in preventing vertical
transmission [2]."
There are some cencerns for the future using of HPV vaccine after the
post implementation assessment data is derived. The reanalysis of cost-
benefit of this new vaccination should be done. Risk and benefit have to
be weighted for making decision.
References
1. Canfell K. Monitoring HPV vaccination programmes
BMJ 2010; 340: c1666.
2. Smith EM, Parker MA, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP.
Evidence for vertical transmission of HPV from mothers to infants. Infect
Dis Obstet Gynecol. 2010;2010:326369.
Competing interests:
None declared
Competing interests: No competing interests